Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Chinese Patent Office
Healthtrust
Colorcon
Baxter
Moodys
Cerilliant
US Department of Justice

Generated: February 16, 2019

DrugPatentWatch Database Preview

Exemestane - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for exemestane and what is the scope of exemestane freedom to operate?

Exemestane is the generic ingredient in two branded drugs marketed by Pharmacia And Upjohn, Alvogen Malta, Cipla, Mylan Pharms Inc, Upsher Smith Labs, West-ward Pharms Int, and Zydus Pharms Usa Inc, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are fifteen drug master file entries for exemestane. Nine suppliers are listed for this compound.

Pharmacology for exemestane
Drug ClassAromatase Inhibitor
Mechanism of ActionAromatase Inhibitors

US Patents and Regulatory Information for exemestane

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
West-ward Pharms Int EXEMESTANE exemestane TABLET;ORAL 077431-001 Apr 1, 2011 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Alvogen Malta EXEMESTANE exemestane TABLET;ORAL 200898-001 Jul 28, 2014 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Pharms Inc EXEMESTANE exemestane TABLET;ORAL 203315-001 Mar 10, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn AROMASIN exemestane TABLET;ORAL 020753-001 Oct 21, 1999 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Zydus Pharms Usa Inc EXEMESTANE exemestane TABLET;ORAL 202602-001 Oct 3, 2018 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Cipla EXEMESTANE exemestane TABLET;ORAL 210323-001 Apr 27, 2018 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for exemestane

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pharmacia And Upjohn AROMASIN exemestane TABLET;ORAL 020753-001 Oct 21, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Pharmacia And Upjohn AROMASIN exemestane TABLET;ORAL 020753-001 Oct 21, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
QuintilesIMS
Merck
Queensland Health
Mallinckrodt
Express Scripts
Fuji
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.